Studies should assess the impact of temporal advances in systemic therapies on trends in stage-specific survival rates for subgroups defined by tumor markers (ER, PR, and HER2) in addressing the hypothesis of the Will Rogers phenomenon. Here, ERBB2 is linked to neoplasm.